Cellectar Biosciences, Inc. 8K

Cellectar Biosciences reported Q2 2026 results, advanced its iopofosine I‑131 and CLR 125 clinical programs, outlined plans for a mid‑2027 NDA submission under accelerated approval, and strengthened its balance sheet through a May 2026 financing.

On August 13, 2026, Cellectar Biosciences, Inc. reported its financial results for the quarter ended June 30, 2026 and provided corporate updates, highlighting progress of its lead radiopharmaceutical, iopofosine I-131, including presentation of positive Phase 2b CLOVER WaM data in relapsed/refractory Waldenström macroglobulinemia, initiation of site activation for a Phase 3 confirmatory trial intended to support a mid‑2027 New Drug Application under the FDA’s Accelerated Approval Program, and publication of supportive Phase 1 multiple myeloma data; the company also announced first patient dosing in a Phase 1b trial of CLR 125 in triple‑negative breast cancer, scheduled an August 18, 2026 webinar on its Phospholipid Drug Conjugate platform, and detailed the impact of a May 2026 approximately $35 million upfront plus up to $105 million milestone‑based financing on its liquidity and operating runway into the second quarter of 2027, along with increased R&D expenses, reduced G&A expenses, and a higher quarterly net loss.

Filing Facts

CIK

1279704

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-095460

Alert Tier

6